Tagrix

80 mg

Product Name: Tagrix
Generic Name: Osimertinib

Description:
Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively targets both EGFR-sensitizing mutations and the T790M resistance mutation in non-small cell lung cancer (NSCLC). It works by blocking the signals that promote the growth of cancer cells.

Dosage Form:
Typically available as oral tablets.

Common Dosages:

• 40 mg tablets

• 80 mg tablets (most common dose)

Indications:

• Treatment of patients with metastatic EGFR T790M mutation-positive NSCLC

• First-line treatment of patients with EGFR mutation-positive NSCLC

Mechanism of Action:
Osimertinib selectively inhibits mutant forms of EGFR by covalently binding to the ATP-binding site, which prevents phosphorylation and downstream signaling that promotes tumor growth.